Advanced Filters
noise
Found 65,447 clinical trials
B Bin Li, Dr

Qishenyiqi Dripping Pill for Coronary Microvascular Disease

To investigate the efficacy and safety of Qishenyiqi in patients with microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Qishenyiqi on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.

40 - 75 years of age All Phase 4
H Hildur Helgadottir, MD, PhD

SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma

At present two studies (SWOG S1801 and NADINA) have demonstrated superiority when using neoadjuvant treatment compared to adjuvant treatment only, but no studies have compared PD-1 monotherapy (SWOG 1801 regimen) to the PD-1/CTLA-4 combination (NADINA regimen) therapy. The SWE-NEO study aims to compare these two regimens, where the PD-1/CTLA-4 combination …

18 years of age All Phase 3
K Katarina Lundervold

NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals

The purpose of this study is to evalue the effects of nicotinamide adenine dinucleotide (NAD) supplementation (nicotinamide riboside (NR) form) on sleep in healthy adults compared to a placebo. NAD is important for brain health and energy balance and a proposed explanation for its effect on sleep is that NAD …

40 - 60 years of age All Phase 2
T Tamaz Shaburishvili, MD

Reprieve System Pilot Study

The objective of the study is to evaluate the use of the Reprieve System to decongest subjects with acute decompensated heart failure.

18 years of age All Phase N/A
K Kelly Dr. Mathew, MD

Retrograde Versus Antegrade Perfusion in Low-Moderate Hypothermia for Aortic Arch Surgery

The purpose of this study is to compare brain function after surgical circulatory arrest using either antegrade perfusion or retrograde perfusion.

18 years of age All Phase N/A
Z Zhenni Guo

Effect of RIC on Cerebral Autoregulation in Patients Undergoing Cerebrovascular Stent Implantation

The purpose of this study is to determine the effect of remote ischemic conditioning on cerebral autoregulation in patients undergoing cerebrovascular stent implantation.

18 years of age All Phase N/A
J James B. Elder, MD

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

This phase I trial tests the safety, side effects, and best dose of anti-glycoprotein-A repetitions predominant (GARP) chimeric antigen receptor (CAR) T cell therapy and how well it works in treating patients with grade III or IV gliomas that have come back after a period of improvement (recurrent). CAR T-cell …

18 years of age All Phase 1
O Olive Lennon

Exoskeleton Training for Spinal Cord Injury Neuropathic Pain (ExSCIP)

The goal of this feasibility trial is to learn if exoskeleton or robotic walking works to reduce nerve (neuropathic) pain after spinal cord injury. This study asks is: Providing walking practice through use of a robotic device (exoskeleton) three times per week for twelve weeks possible to deliver? Would people …

18 - 90 years of age All Phase N/A

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults

The purpose of this study is to learn about the safety of the study medicine called PF-08049820 in healthy adults. The study will also see: how the body processes the study medicine and if food affects the amount of study medicine in the blood. The study medicine is developed for …

18 - 65 years of age All Phase 1
P Pei miao Zhang

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, as well as preliminary efficacy of mRNA encoding CD19/CD3 T cell engager (ABO2203) in adult patients with relapsed or refractory CD19-positive B-NHL, This study included dose escalation and dose expansion parts.

18 - 75 years of age All Phase 1

Simplify language using AI